The DOI matches its Crossref record.
Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts
Open accessAbstract
Numerous human tumor types, including ovarian cancer, display a significant expression of the CD44 family of cell surface proteoglycans. To develop tumor-targeted drugs, we have initially evaluated whether the CD44 ligand hyaluronic acid (HA) could serve as a backbone for paclitaxel (TXL) prodrugs. HA-TXL was prepared by modification of previous techniques. The in vitro cytotoxicity of HA-TXL against the CD44(+) human ovarian carcinoma cell lines SKOV-3ip and NMP-1 could be significantly blocked by preincubation with a molar excess of free HA. Female nude mice bearing intraperitoneal implants of NMP-1 cells were treated intraperitoneally with a single sub-maximum tolerated dose dose of HA-TXL or with multiple-dose regimens of paclitaxel (Taxol; Mead Johnson, Princeton, NJ) to determine the effects of these regimens on host survival and intraperitoneal tumor burden, with the latter being assessed by magnetic resonance imaging. NMP-1 xenografts were highly resistant to Taxol regimens, as host survival was only nominally improved compared to controls (T//C approximately 120), whereas single-dose HA-TXL treatment significantly improved survival in this model (T//C approximately 140; P = .004). In both NMP-1 and SKOV-3ip models, MR images of abdomens of HA-TXL-treated mice obtained shortly before controls required humane sacrifice revealed markedly reduced tumor burdens compared to control mice. This study is among the first to demonstrate that HA-based prodrugs administered locoregionally have antitumor activity in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293
Hyaluronic acid for anticancer drug and nucleic acid delivery
Dosio, F., Arpicco, S., Stella, B., & Fattal, E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.011 · Cited by 596
Self-assembled hyaluronic acid nanoparticles for active tumor targeting
Choi, K. Y., Chung, H., Min, K. H., Yoon, H. Y., Kim, K., Park, J. H., Kwon, I. C., & Jeong, S. Y. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.030 · Cited by 578
Platt, V. M., & Szoka, F. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800024g · Cited by 456
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403
Smart Nanocarrier Based on PEGylated Hyaluronic Acid for Cancer Therapy
Choi, K. Y., Yoon, H. Y., Kim, J.-H., Bae, S. M., Park, R.-W., Kang, Y. M., Kim, I.-S., Kwon, I. C., Choi, K., Jeong, S. Y., et al. (2011) · ACS Nano · doi:10.1021/nn202070n · Cited by 399
Polymeric nanostructured materials for biomedical applications
Tang, Z., He, C., Tian, H., Ding, J., Hsiao, B. S., Chu, B., & Chen, X. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.05.005 · Cited by 363
PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo
Choi, K. Y., Min, K. H., Yoon, H. Y., Kim, K., Park, J. H., Kwon, I. C., Choi, K., & Jeong, S. Y. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.010 · Cited by 336
Upadhyay, K. K., Bhatt, A. N., Mishra, A. K., Dwarakanath, B. S., Jain, S., Schatz, C., Le Meins, J.-F., Farooque, A., Chandraiah, G., Jain, A. K., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.12.043 · Cited by 316
Prodrug-based intracellular delivery of anticancer agents
Bildstein, L., Dubernet, C., & Couvreur, P. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.12.005 · Cited by 310
Choi, K. Y., Min, K. H., Na, J. H., Choi, K., Kim, K., Park, J. H., Kwon, I. C., & Jeong, S. Y. (2009) · Journal of Materials Chemistry · doi:10.1039/b900456d · Cited by 272
Choi, K. Y., Saravanakumar, G., Park, J. H., & Park, K. (2012) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2011.10.029 · Cited by 264
Yao, J., Zhang, L., Zhou, J., Liu, H., & Zhang, Q. (2013) · Molecular Pharmaceutics · doi:10.1021/mp3005808 · Cited by 87
Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells
Han, Shin, D. H., Kim, J. S., Weon, K. Y., Jang, C.-Y., & Kim, J.-S. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s95850 · Cited by 65
Tirella, A., Kloc-Muniak, K., Good, L., Ridden, J., Ashford, M., Puri, S., & Tirelli, N. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.032 · Cited by 60
Metadata
- Authors
- Auzenne, E., Ghosh, S. C., Khodadadian, M., Rivera, B., Farquhar, D., Price, R. E., Ravoori, M., Kundra, V., Freedman, R. S., & Klostergaard, J.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2007-06
- Volume
- 9
- Issue
- 6
- Pages
- 479-486
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2154180494
- Cited by
- 159
- References
- 0
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.